Blood Podcast Prolonged response after stopping TPO-RA in ITP, TP53 mutations and myelofibrosis outcomes, clinical picture of ERCC6L2 disease, where variants predispose to marrow failure and malignancy
14 snips
Jun 8, 2023 Chapters
Transcript
1 2 3 4 5 6 7 8
Introduction
00:00 • 3min
The Proportion of Sustained Complete Response to T-PoRA's at 24 and 52 Weeks After Treatment Cessation
02:34 • 2min
The Role of T-PoRA's in Sustained Responses to Initial Treatment
04:30 • 4min
The Impact of T-P53 Mutations on Myelofibrosis
08:02 • 4min
The Clinical Picture of the ERCC 6L2 Disease
11:53 • 3min
The ERCC 6L2 Syndrome and the Pathogenesis of the Disease
14:48 • 2min
The Founder Effect of ERCC 6L2 C1424-Delt on Bone Marrow Failure
16:51 • 3min
The Importance of Early Recognition and Active Surveillance in Patients With ERCC 6L2 Variants
19:41 • 3min